Please login to the form below

Not currently logged in
Email:
Password:

Alnylam

This page shows the latest Alnylam news and features for those working in and with pharma, biotech and healthcare.

AstraZeneca and Ionis sign $3.6bn deal for eplontersen

AstraZeneca and Ionis sign $3.6bn deal for eplontersen

However, if approved, eplontersen will not have the ATTR market to itself and must compete with Pfizer’s Vyndaqel/Vyndamax (tafamidis) and Alnylam’s RNAi therapy Onpattro (patisiran).

Latest news

More from news
Approximately 19 fully matching, plus 46 partially matching documents found.

Latest Intelligence

More from intelligence
Approximately 1 fully matching, plus 6 partially matching documents found.

Latest appointments

  • Editas Medicine adds to board of directors Editas Medicine adds to board of directors

    Alnylam Pharmaceuticals’ Dr Akshay Vaishnaw joins. Cambridge, Massachusetts-based Editas Medicine has appointed Dr Akshay Vaishnaw to its board of directors. ... He has extensive clinical development experience, a passion for scientific excellence, and

  • VC firm expands team, appoints Genzyme and Lilly veterans VC firm expands team, appoints Genzyme and Lilly veterans

    The firm, which focuses on building healthcare companies, has appointed former executives from Genzyme, Lilly, ImClone and Alnylam to help it translate scientific innovation into new companies. ... Also joining Third Rock as venture partners are Daniel

More from appointments
Approximately 0 fully matching, plus 2 partially matching documents found.

Latest from PMHub

  • EPG Health EPG Health

    Strategic planning - to ensure ongoing engagement and success. Alexion, Almirall, Alnylam, AstraZeneca, Bial, Biogen, Bluebird Bio, Boehringer Ingelheim, BMS, CSL Behring, Ferring, Four Health, GSK, HRA Pharma, Janssen, Leo Pharma, Lilly,

  • How do you define a biotech company?

    This approach is particularly apparent in some of the recent examples of technology pioneered by biotech organisations, such as CAR-T technology (Novartis, Juno and Kite Pharma) and RNAi (Alnylam) where 

  • Managing value: Why early asset development and commercialization is important

    For example, Alnylam Pharmaceuticals, with its lead product in Phase III, has a market capitalisation of $7.4 billion, despite having no marketed products; or Achillion Pharmaceuticals with a market capitalisation

More from PMHub
Approximately 0 fully matching, plus 3 partially matching documents found.

Subscribe to our email news alerts

Featured jobs

PMHub

Add my company
Create Health

A healthcare marketing agency that shares your passion for making things better. Our clients with solve real health problems every...

Latest intelligence

Virtual MSL/Sales training programs and events
Top 10 ways to leverage the Impetus InSite Platform® for internal MSL/Sales training programs and events...
6 trends shaping the future of personalized medicine
Senior Consultant Leah Carlisle explores the key trends discussed at the 16th annual Personalized Medicine Conference, providing expert analysis and key recommendations for biopharmaceutical innovators....
Omnichannel strategies to revolutionize the healthcare professional experience
Fishawack Health’s omnichannel experts unite to reveal how medical and commercial teams can build more meaningful experiences for healthcare professionals. They discuss the opportunities of omnichannel and explore how the...